Semaglutide pilot program improves glycemic control and tolerability in Cystic Fibrosis-Related Diabetes

Management of Cystic Fibrosis-Related Diabetes (CFRD) is increasingly complex, with a growing prevalence of overweight and obesity in the cystic fibrosis (CF) population, partly due to widespread CFTR modulator use. Traditional insulin-centric approaches may not fully address the metabolic challenges in these patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), known for their glucose-lowering and weight-management benefits, are emerging as a potential adjunctive therapy for CFRD, addressing a critical gap in comprehensive metabolic care.

This pilot implementation program evaluated injectable semaglutide in adults with CFRD. The program followed 11 participants over a 12-month period, focusing on practical aspects of therapy integration. Key objectives included assessing patient selection criteria, establishing appropriate monitoring protocols, and developing strategies for managing potential adverse effects specific to this unique patient population. The study aimed to provide real-world insights into the feasibility and considerations for using GLP-1R agonists as an adjunct to insulin in CFRD management.

The pilot program observed that the majority of 11 participants tolerated injectable semaglutide well over 12 months, with no unexpected severe adverse events reported. Importantly, participants demonstrated clinically meaningful improvements in glycemic control, suggesting a positive impact on CFRD management. The study highlighted that careful patient selection, robust monitoring protocols, and proactive management of potential adverse effects were crucial for successful implementation of GLP-1R agonist therapy in this specific patient group. These findings underscore the importance of individualized care and close follow-up when introducing GLP-1R agonists in a complex population like CFRD patients. This pilot demonstrated the potential for GLP-1R agonist therapy as an adjunct to insulin.

This pilot program revealed that semaglutide can be a well-tolerated and effective adjunct to insulin for improving glycemic control in carefully selected adults with Cystic Fibrosis-Related Diabetes.